Updates are available New version dated 2023-11-09

Click to view New version: https://doi.org/10.29328/journal.jnnd.1001087

Bimatoprost Ophthalmic Solution (BOS) 0.3 mg w/v for 1 Open Trial of Long-term Preventive Therapy of Migraine in 3 patients with Pathophysiologic Shift from Brain to Eye

Crossref DOI link: https://doi.org/10.29328/journal.jnnd.1001087

Published Online: 2023-11-09

Published Print: 2023-11-09

Update policy: https://doi.org/10.29328/crossmark-policy

About CrossMark